Vaccinia-virus-based vaccines are expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus

HIGHLIGHTS

  • who: Syed Faraz Ahmed and collaborators from the Department of Electrical and Electronic Engineering, University of Melbourne, Parkville, VIC, Australia have published the research: Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus, in the Journal: Viruses 2022, 14, 1960. of 23/07/2022
  • what: By investigating genetic variation with respect to orthologous immunogenic vaccinia-virus proteins the authors report data that anticipates immune responses induced by VACV-based vaccines including the currently available and vaccines to remain highly cross-reactive against the newly observed A.A . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?